InvestorsHub Logo
Followers 13
Posts 3229
Boards Moderated 0
Alias Born 11/25/2020

Re: None

Monday, 02/05/2024 2:27:06 PM

Monday, February 05, 2024 2:27:06 PM

Post# of 404332
I think I found a pearl in the last quarterly report: Licensing fees decreased by $0.7 million, or 54%. This decrease is primarily due to the expiration of the marketing alliance agreements between the Company and Lannett Company, Inc. dated March 6, 2019 and April 9, 2019 (the "Lannett Agreements”) on March 31, 2023. The revenue streams that were generated during periods ending on or prior to March 31, 2023 and attributed to the Lannett Agreements, included profit splits on the sale by Lannett of Amphetamine IR and Amphetamine ER. Since April 1, 2023, these products are now sold by the Company under its own label, with revenues being recorded as manufacturing revenues instead of licensing fees going forward.
-------------------
I think we are STILL THE MANUFACTTURER OF ADDERAL FOR LANNETT... Thoughts?

-----------------
6 minutes left for editing the post - it could just be that whatever material was received by Lannett that was not paid by Lannett as Licensing fee (up to 9 months remember?) was paid as a lump sum on April 1st to Elite as manufacturing fee - which could explain the BUMP in revenues we had last quarter.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ELTP News